



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/263,689	03/05/1999	JIAN NI	1488.0560002	2137

7590 06/02/2006

STERNE KESSLER GOLDSTEIN & FOX  
1100 NEW YORK AVENUE N W  
SUITE 600  
WASHINGTON, DC 200053934

EXAMINER

CANELLA, KAREN A

ART UNIT PAPER NUMBER

1643

DATE MAILED: 06/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)	
	09/263,689	NI ET AL.	
	Examiner	Art Unit	
	Karen A. Canella	1643	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☐ Claim(s) 141-172 a is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) 141-172 a is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.  |

### DETAILED ACTION

1. Claims 141-172 are pending and under consideration.
2. Sections of Title 35, U.S. Code, not found in this action can be found in a prior action.
3. The rejection of claims 141-172 under 35 U.S.C. 101 because the claimed invention is not supported by either a specific, substantial asserted utility or a well-established utility. The instant invention is drawn to the protein of SEQ ID NO:4 and fragments of SEQ ID NO:4 which consist of at least 30 or 50 contiguous amino acid sequence of SEQ ID NO:4 as well as specific antigenic fragments of SEQ ID NO:4, predicted by the specification to have antigenic activity such as residues 62-102 of SEQ ID NO:4, residues 226-259 of SEQ ID NO:4 and residues 197-308 of SEQ ID NO:4. The specification identifies SEQ ID NO:4 as belonging to the Galectin family of proteins recognized to have the ability to bind beta-galactoside in a calcium-independent manner. The art teaches that members of this class are distinguished from other lectins by the presence of a conserved carbohydrate recognition domain. The instant specification lacks a specific, substantial asserted utility because it fails to provide for a non-ambiguous usage of the claimed protein. On page 27, lines 20-25, the specification states

*It is believed that certain tissues in mammals with certain diseases (cancer, autoimmune diseases, inflammatory diseases, asthma, and allergic diseases) express significantly altered (enhanced or decreased) levels of the galectin 8, 9, 10, or 10SV protein and mRNA encoding the galectin 8, 9, 10, or 10SV protein when compared to a corresponding "standard" mammal, i.e., a mammal of the same species not having the disease.*

It is noted with particular emphasis that the specification fails to assert if the claimed protein is over-expressed or under-expressed in any of the stated diseases. Because of this defect the stated utility is neither specific nor substantial because the condition of perhaps being over expressed or perhaps being under-expressed does not provide for a specific, substantial assertion.

It is further noted that the specification contemplates on page 29, lines 3-5,

Art Unit: 1643

*The present invention is useful for detecting diseases in mammals (for example, cancer, autoimmune diseases, inflammatory diseases, asthma, and allergic diseases), and on page 30, lines 14-18,*

*The ability of galectin 8, 9, 10, or 10SV to modulate growth regulatory activity may be therapeutically valuable in the treatment of clinical manifestations of such cell regulatory disorders. Disorders which can be treated include, but should not be limited to, autoimmune disease, cancer (preferably, melanoma, renal, astrocytoma, and Hodgkin disease), inflammatory disease, wound healing, arteriosclerosis, other heart diseases, microbe infection (virus, fungal, bacterial, and parasite), asthma, and allergic diseases.*

However, no further information is given with regard to detecting an over expression or an under expression of SEQ ID NO:4 for the detection of cancer, autoimmune diseases, inflammatory diseases, asthma, and allergic diseases in mammal and no further information is given with regard to the need to decrease or increase the level of SEQ ID NO:4 for the treatment of autoimmune disease, cancer, inflammatory disease, wound healing, arteriosclerosis, other heart diseases, microbe infection, asthma, and allergic diseases. Further, as stated in the Office action of February 1, 2001 (page 4, line 15 to page 5, line 2), membership in the family of galectins does not confer a specific substantial utility to the instant SEQ ID NO:4 because the family encompasses proteins having widely different functions. Further, the ability to bind beta-galactoside in a calcium-independent manner does not provide a specific, substantial utility because that property is shared by numerous proteins of the galectin family, which as stated above, have widely differing functional attributes. It is therefore concluded that the instant specification lacks a specific, substantial and asserted utility for SEQ ID NO:4.

4. The rejection of Claims 141-172 under 35 U.S.C. 112, first paragraph because the claimed invention is not supported by either a specific, substantial and credible asserted utility or a well established utility for the reasons set forth above, and one skilled in the art clearly would not know how to use the claimed invention is therefore maintained for reasons of record.

Art Unit: 1643

5. Applicant has previously argued that the rejection of the post-filing date references for establishing the specific and substantial utility of the instant invention are not appropriate because the case law cited is directed to enablement rather than utility. Applicant further argued that it is well-known that post-filing date references and subsequently-generated data can be used to support the credibility of a utility asserted in the specification. The post-filing date reference of Sat et al (Glycobiology, 2002, Vol. 12, pp. 191-197) teach that galectin-9 which is identical to the instant SEQ ID NO:4, is a eosinophil chemoattractant. The post filing reference of Hirashima et al (International Archives of Allergy and Immunology, 2000, Vol. 122, suppl 1, pages 6-9) teaches that there is a correlation between heightened eosinophil activity and asthma. The combination of references would corroborate the specification claims to a treatment or diagnosis of asthma if there was such an asserted utility for the over-expression of SEQ ID NO:4 and the condition of asthma. However, the specification fails to provide this assertion because it contemplates that the claimed polypeptides can be either over expressed or under-expressed in the condition of asthma. Therefore the post filing date references have no bearing on the specification as filed. A statement that the polypeptide of may be over expressed in a given disease state or may be over expressed in a given disease state is tantamount to no assertion at all. The submission of the post-filing reference indicating the usefulness of the claimed polypeptide can not be used to confirm the credibility of the asserted utility when the specification is lacking an asserted utility.

6. Applicant maintains that because the invention has been shown to have at least one of the stated utilities, the claims meet the requirements of 35 U.S.C. 101. this has been considered but not found to be persuasive for the reasons set forth above.

7. The rejection of claims 166-172 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is maintained for reasons of record. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention..

Art Unit: 1643

The specification states on page 26, lines 16-19 that antigenic-epitope bearing peptides and polypeptides of the invention preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Claims 166 and 168-172 encompass any fragment of SEQ ID NO:4 having at least 30 contiguous amino acids of SEQ ID NO:4 without regard as to any functional characteristic of the fragment. The specification further states on page 26, line 23 that the antigenic polypeptides identified from SEQ ID NO:4 are residues 62-101, 226-259 and 197-308. Claims 166-173 read on fragments of SEQ ID NO:4 which include fragments outside of the specific regions, such as fragments taken from residues 1-61 and residues 102-198. The specification fails to teach how to use said broadly claimed fragments of SEQ ID NO:4.

It is well known in the art that polypeptides are folded 3-dimensional structures, the function and stability of which are directly related to a specific conformation (Mathews and Van Holde, Biochemistry, 1996, pp. 165-171, cited in a previous Office action). In any given polypeptide, amino acids distant from one another in the primary sequence may be closely located in the folded, 3-dimensional structure (Mathews and Van Holde, Biochemistry, 1996, pp. 166, figure 6.1). The specific conformation of a polypeptide results from non-covalent interactions between amino acids, beyond what is dictated by the primary amino acid sequence. Fragments of SEQ ID NO:4 taken out of the context of the entirety of SEQ ID NO:4 can potentially have radically altered three dimensional structure relative to the corresponding three dimensional structure within the SEQ ID NO:4 environment (Matthews, B. "Genetic and Structural Analysis of the Protein Stability Problem", cited in a previous Office action). Thus, the consequences of the altered sequence environment cannot be predicted. Due to these reasons, one of skill in the art would be forced into undue experimentation in order to use the broadly claimed invention.

Further, it is recognized in the art (Burch WO 03/084467) that putative epitopes can be predicted using a computer to scan the sequence of a protein for amino acid sequences that contain a "motif" or a defined pattern of amino acid residues associated with a particular MHC allele, but that the vast majority of these predicted epitopes fail to be immunogenic (page 5, lines 18-21). Therefore, given the lack of teachings in the specification regarding how to use such a

Art Unit: 1643

fragment of the claimed sequence which is not immunogenic, one of skill in the art would be subject to undue experimentation in order to use the broadly claimed fragments.

8. Applicant argues that use of protein fragments to raise an antibody is well known in the art, and therefore the above claims are enabled. This has been considered but not found persuasive. Claim 166-172 are drawn to any protein fragment of SEQ ID NO:4, not just protein fragments that would elicit an antibody which would bind to the native protein.

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

An obviousness-type double-patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim is either anticipated by, or would

Art Unit: 1643

have been obvious over, the reference claim(s). See, e.g. In reBerg, 140 F.3d, 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

10. Claim 145 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 12 of U.S. Patent No. 6,468,768. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claim of the '768 patent anticipated the instant claim 145.

11. Claims 145 and 149 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 23 of U.S. Patent No. 6,027,916. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claim of the '916 patent anticipates the instant claim.

12. The rejection of claims 166-172 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is withdrawn in light of applicant's arguments.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 11 am to 10 pm, except Wed, Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Art Unit: 1643

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Karen A. Canella, Ph.D.

5/29/2006

  
KARENA. CANELLA PH.D  
PRIMARY EXAMINER